CN102858357A - A pharmaceutical composition and a health functional food composition for preventing, treating or improving a gastrointestinal dyskinetic disease - Google Patents
A pharmaceutical composition and a health functional food composition for preventing, treating or improving a gastrointestinal dyskinetic disease Download PDFInfo
- Publication number
- CN102858357A CN102858357A CN2011800084088A CN201180008408A CN102858357A CN 102858357 A CN102858357 A CN 102858357A CN 2011800084088 A CN2011800084088 A CN 2011800084088A CN 201180008408 A CN201180008408 A CN 201180008408A CN 102858357 A CN102858357 A CN 102858357A
- Authority
- CN
- China
- Prior art keywords
- gastrointestinal
- composition
- compositions
- rhizoma coptidis
- herbal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention provides a pharmaceutical composition for the prevention or treatment of gastrointestinal dyskinetic diseases and a health functional food composition for the prevention or improvement of gastrointestinal dyskinetic diseases, comprising a combination of two or more selected from the group consisting of Bupleuri Radix, Coptidis Rhizoma and Glycyrrhizae Radix et Rhizoma. The composition according to the present invention comprises a combination of two or more of Bupleuri Radix, Coptidis Rhizoma and Glycyrrhizae Radix et Rhizoma, and significantly facilitates gastrointestinal motility, in particular, gastric emptying rate and gastrointestinal transit, thereby being used for the prevention, improvement, or treatment of gastrointestinal dyskinetic diseases, in particular, functional dyspepsia associated with gastric emptying rate or gastrointestinal transit.; In addition, the composition according to the present invention consists of natural substances, and thus there is little concern regarding undesirable toxicity.
Description
Technical field
The present invention relates to for the pharmaceutical composition and the healthy functions food compositions that prevent, treat or improve the gastrointestinal motility obstacle disease, more particularly, the present invention relates to for prevention or the pharmaceutical composition for the treatment of gastrointestinal motility obstacle disease and the healthy functions food compositions that is used for preventing or improving the gastrointestinal motility obstacle disease, described compositions comprises medical herbs complex (herb complex).
Background technology
Functional dyspepsia (FD) is a kind of multifactorial disease, caused by many factors of curing the disease, comprising: gastroxia, gastrointestinal motility are undesired, internal organs super quick, helicobacter pylori (Helicobacter pylori) infects, the local excitation factor raises, stress and inherited genetic factors.It is that more than one abdominal pains or discomfort are the syndrome of feature, and be diagnosed as: endoscope, histology and biochemical analysis do not have the performance of organs abnormality upper gastrointestinal is accidental, and its pathology characteristic is unclear.Uncomfortable clinical symptoms is: epigastrium is glutted, morning is full, tympanites, feel sick, belch, vomiting and retch, these symptoms may be to make up appearance arbitrarily.
Although functional dyspepsia is not fatal, it is widely current, and is along with the raising that quality of life is paid attention to, growing to the concern of this disease.Yet different from other digestive disease as mentioned above, the definition of this disease and pathophysiology characteristic be not clear elaboration also, and therefore in fact also not treatment suggestion does not also have medicine to be proved to be treating effectively in clinical practice.In addition, 20% to 60% functional dyspepsia patient shows has doing well,improving to placebo treatment, has therefore hindered the assessment of Drug therapy experiment.
Gastrointestinal motility by autonomic Antagonism double innervation regulation and control, also is subject to the adjusting of the heterogeneous equilibrium of excited and the inhibitory nerve factor usually.The terminal acetylcholine (ACh) that discharges of cholinergic nerve promotes gastrointestinal motility, its effect is stopped by acetylcholinesterase (AChE), yet the dopamine receptor that exists on the preganglionic fibre of dopamine and cholinergic nerve (D2) interacts, suppress the effect of ACh, and then caused gastrointestinal motility to descend.The primary treatment agent of gastrointestinal motility obstacle disease comprises short digestive tract power reinforcing medicine, bisfentidine, PPI(proton pump inhibitor).
Especially, helicobacter pylori infections is occurred frequently in the dyspepsia ulcer sample or dyskinesia sample, it is reported, 68% functional dyspepsia patient has in fact infected helicobacter pylori.In fact, the dyspepsia of ulcer sample is treated with urging digestive tract power reinforcing medicine (metoclopramide, domperidone, mosapride etc.) or antidepressants or antianxiety drugs with bisfentidine and PPI treatment, the dyspepsia of dyskinesia sample.
Short digestive tract power reinforcing medicine activates medicine as anti-dopamine agents, serotonin and/or motilin agonists works stimulating gastrointestinal road smooth muscle contraction, remove and gastric emptying thereby improve the sphincteral esophagus that stress and promote of downstream gastrointestinal tract, and then shorten the gastrointestinal tract transmission time.Medicine as digestive tract power reinforcing medicine or Bendectin comprises at present: the medicines such as metoclopramide, domperidone, cisapride, support Billy, levosulpiride, mosapride.These medicines are strengthened gastrointestinal motility, improve by this digestion symptom that dumping syndrome or chronic gastritis accompany, but possible side effect meeting has problems in these drug uses.
Metoclopramide (Metoclopramide) or domperidone (domperidone) antagonism d2 dopamine receptor move with stimulating gastrointestinal.Metoclopramide improves myenteric plexus and discharges ACh, but domperidone is without this function.Therefore, the former is subject to the inhibition of cholinergic antagonist, and the latter is not subjected to the inhibition of cholinergic antagonist.In addition, these medicines may have side effects, and comprise central nervous system's side effect, nipple discharge and gynecomastia.
Cisapride is the prescription drugs commonly used of functional dyspepsia, and its 5-HT4 receptor that activates the gastrointestinal tract myenteric plexus is to promote ACh to discharge and to improve the gastrointestinal physiological movement.Cisapride is the antagonism d2 dopamine receptor not, so it does not have the preventing or arresting vomiting effect.But it is disabled because of potential fatal arrhythmia risk.
Rely on Billy's antagonism d2 dopamine receptor, also suppress AChE, therefore activate gastrointestinal motility by synergism.
Similar with cisapride, mosapride activates the 5-HT2 receptor to promote gastrointestinal motility.It lacks the antagonism for d2 dopamine receptor, does not therefore cause disadvantageous central nervous system's effect.
Functional dyspepsia is a kind of common functional gastrointestinal imbalance relevant with psychentonia, therefore with neuropathy, anxiety and depression.So the social psychology intervention may have effect in treatment, and coupling west and oriental medicinal drug have better effect for the improvement of multi-factor disease symptom.Therefore, having the pathogenetic functional dyspepsia of multiple-factor can not fully treat with a class medicine, the short digestive tract power reinforcing medicine that needs exploitation to have number of mechanisms.
Said medicine has shown effect for gastrointestinal motility disorders, but causes the toxic and side effects problem.Therefore be necessary to develop be used for the treatment of, improvement or prophylactic function dyspepsia and do not cause safe drugs and the compositions of side effect.
Simultaneously, Radix Bupleuri (Bupleuri Radix) is the root of Bupleurum (Bupleurum falcatum L) or its kind, and Radix Bupleuri is the herbaceos perennial of umbellate form section.Dry sample should contain 0.3% or more saikoside a (C
42H
68O
13: 780.99), stem or leaf should be no more than 10%, and ash is no more than 6.5%, are insoluble to the no more than 2.0%[Pharmacopoeia Coreana of ash of acid, and the 9th edition, 2007].Radix Bupleuri was gathered in the crops in spring and autumn, removed aerial parts and soil, and is dry under the sunlight.Its component comprises: oil, bupleurumol, fatty acid, sugar and saponin, its pharmacotoxicological effect comprises: anti-inflammatory, bring down a fever, diuresis, antiulcer, calmness and spasmolytic, and disease-resistant former effect [Bo-sup Jung, Min-Kyo Shin. Korean native medicine pharmacopeia (herbal medicine), Yeongnimsa, 2003:412-414].
Rhizoma Coptidis (Coptis Rhizoma) is the rhizome of almost removing the root of Coptis japonica (Coptis japonica Makino), Rhizoma Coptidis (Coptis chinensis Franchet) or Coptis teeta (Coptis teeta Wallich), and Coptis japonica, Rhizoma Coptidis or Coptis teeta are the herbaceos perennials of Ranunculaceae.Based on the medicinal herbs of drying, it should contain 4.2% or more berberine [berberine hydrochloride (C
20H
18ClNO
4: 371.81)], loss on drying should not surpass 9.0%, and ash should be more than 4.0%, and the ash that is insoluble to acid should be more than the 1.05%[Pharmacopoeia Coreana, and the 9th edition, 2007].Rhizoma Coptidis results in autumn are removed leaf, root and soil.Under the sun, after the drying, remove phellem layer (cork layer).It contains alkaloid, such as berberine, coptisine, 13-methyl-.psi.-coptisine., Columbamine (palmatine) and jateorhizine (jateorrhizine), obacunone and obakulactone as main component, its pharmacotoxicological effect comprises: anti-inflammatory, antiulcer, anticancer, radioprotective, antimicrobial and anti-etiologic agent [[Bo-sup Jung, Min-Kyo Shin. Korean native medicine pharmacopeia (herbal medicine), Yeongnimsa, 2003:490-493].
Radix Glycyrrhizae (Glycyrrhizae Radix et Rhizoma) is root and the rhizome of Radix Glycyrrhizae (Glycyrrhiza uralensis Fischer), G1ycyrrhiza glabra (Glycyrrhiza glabra Linn) or Glycyrrhiza inflata Bat. (Glycyrrhiza infiata Bat.), and Radix Glycyrrhizae, G1ycyrrhiza glabra or Glycyrrhiza inflata Bat. are the herbaceos perennials of pulse family.Based on the medicinal herbs of drying, it should comprise 2.5% or more glycyrrhizic acid ((C
42H
62O
16: 822.93) and 0.7% or more glycyrrhizin (C
15H
12O
4: 256.27), loss on drying should not surpass 12.0%, and ash should not surpass 7.0%, and the ash that is insoluble to acid should not surpass 2.0%[Pharmacopoeia Coreana, the 9th edition, 2007].Root is gathered in the crops in the fall.After removing the branch and radicula of rhizome, Qie Gen is also dry in the sun.The main component that it comprises has saponin, glycyrrhizin, biosone (uralenic acid) and the flavonoid based on triterpene, its pharmacotoxicological effect comprises: detoxifcation, secretion of urine inhibition, cough-relieving, antiinflammatory, antiallergic, antiulcer and effect [the Bo-sup Jung that protects the liver, Min-Kyo Shin. Korean native medicine pharmacopeia (herbal medicine), Yeongnimsa, 2003:684-687].
Known Radix Bupleuri, Rhizoma Coptidis and Radix Glycyrrhizae have antiulcer action separately, but they yet there are no report for the treatment effect of functional dyspepsia.Traditionally, oriental medicinal drug (such as Sini San (frigid extremities powder) and Rhizoma Pinelliae soup XIEXIN TANG (Pinellia Decoction to Drain the Epigastrium)) past always only with to gastrointestinal motility and resultful other therapy couplings of digestive disorders tool that stress cause to improve symptom.The result shows, isoliquiritigenin (isoliquiritigenin)-a kind of flavone that separates from Radix Glycyrrhizae-conciliate two kinds of effects of spasm and play the effect of regulating the gastrointestinal transmission by the spasm that causes to gastrointestinal transmission spasm.Drawing convulsive effect and may relate to the activation of muscarinic receptor, mainly is .Phytother.Res.2009 such as [, 23:498-506] Chen G. due to the calcium channel blocking-up and separate the spasm effect.
Summary of the invention
Technical problem
Therefore, the inventor recognize develop a kind of for prevention, improve or the compositions for the treatment of gastrointestinal motility obstacle disease, and they have done many effort and develop and a kind ofly have good efficacy and the less pharmaceutical composition of side effect.They have developed a kind of and similarly medical herbs combination of mosapride (a kind of widely used short digestive tract power reinforcing medicine), thereby have finished the present invention.
Technical scheme
Therefore, the purpose of this invention is to provide a kind of pharmaceutical composition that effectively is used for prevention or treatment gastrointestinal motility obstacle disease, described pharmaceutical composition contains medical herbs mixture as active component.
Another object of the present invention provides a kind of effective healthy functions food compositions for preventing or improve the gastrointestinal motility obstacle disease, and described compositions contains medical herbs mixture as active component.
Beneficial effect
As mentioned above, compositions of the present invention comprises two or more the combination in Radix Bupleuri, Rhizoma Coptidis and the Radix Glycyrrhizae, thereby improves significantly the gastrointestinal motility obstacle disease, particularly gastric emptying speed and gastrointestinal transmission.Therefore, said composition is representing unexpected effect in the gastrointestinal disorder due to prevention, improvement or the treatment functional dyspepsia.In addition, it also comprises the medical herbs of for a long time tradition use, does not therefore almost have the worry of adverse side effect or toxicity.
In order to achieve the above object, the invention provides a kind of pharmaceutical composition for prevention or treatment gastrointestinal motility obstacle disease, described compositions comprises two or more the combination that is selected from Radix Bupleuri, Rhizoma Coptidis and the Radix Glycyrrhizae.In addition, the invention provides the method for a kind of prevention or treatment gastrointestinal motility obstacle disease, comprise to the object drug administration compositions that these needs are arranged, described pharmaceutical composition comprises two or more the combination that is selected from Radix Bupleuri, Rhizoma Coptidis and the Radix Glycyrrhizae.In addition, the invention provides a kind of pharmaceutical composition for prevention or treatment dyskinesia disease, described pharmaceutical composition comprises two or more the combination that is selected from Radix Bupleuri, Rhizoma Coptidis and the Radix Glycyrrhizae.In addition, the invention provides the application of a kind of pharmaceutical composition in the medicine of preparation prevention or treatment dyskinesia disease, described pharmaceutical composition comprises two or more the combination that is selected from Radix Bupleuri, Rhizoma Coptidis and the Radix Glycyrrhizae.
In addition, the invention provides a kind ofly for prevention or improve the healthy functions food compositions of gastrointestinal motility obstacle disease, described compositions comprises two or more the combination that is selected from Radix Bupleuri, Rhizoma Coptidis and the Radix Glycyrrhizae.In addition, the invention provides a kind of method of preventing or improving the gastrointestinal motility obstacle disease, comprise to the object that these needs are arranged and use the healthy functions food compositions, said composition comprises two or more the combination that is selected from Radix Bupleuri, Rhizoma Coptidis and the Radix Glycyrrhizae.In addition, the invention provides a kind of healthy functions food compositions for use in prevention or improve dyskinesia disease, said composition comprises two or more the combination that is selected from Radix Bupleuri, Rhizoma Coptidis and the Radix Glycyrrhizae.In addition, the invention provides a kind of healthy functions food compositions in preparation prevention or improve application in the medicine of dyskinesia disease, said composition comprises two or more the combination that is selected from Radix Bupleuri, Rhizoma Coptidis and the Radix Glycyrrhizae.
The below will describe the present invention in detail.
The inventor is devoted to develop a kind of effective promotion gastrointestinal motility and the herbal-composition that do not cause side effect, they find, (Radix Bupleuri, Rhizoma Coptidis and Radix Glycyrrhizae are the medical herbs of knowing to be selected from two or more combination in Radix Bupleuri, Rhizoma Coptidis and the Radix Glycyrrhizae by use, and almost be free from side effects), can promote gastrointestinal motility.Therefore two or more the combination that is selected from Radix Bupleuri, Rhizoma Coptidis and the Radix Glycyrrhizae can or improve the active component of the healthy functions food compositions of gastrointestinal disease as active component and the prevention of the pharmaceutical composition of prevention or treatment gastrointestinal disease.
On the one hand, the invention provides a kind of pharmaceutical composition for prevention or treatment gastrointestinal motility obstacle disease, described pharmaceutical composition comprises two or more the combination that is selected from Radix Bupleuri, Rhizoma Coptidis and the Radix Glycyrrhizae.
On the other hand, the invention provides a kind ofly for prevention or improve the healthy functions food compositions of gastrointestinal motility obstacle disease, described compositions comprises two or more the combination that is selected from Radix Bupleuri, Rhizoma Coptidis and the Radix Glycyrrhizae.
Hereinafter use " herbal-composition " as the term that comprises pharmaceutical composition and healthy functions food compositions.
In herbal-composition, the proportion of composing of Radix Bupleuri, Rhizoma Coptidis and Radix Glycyrrhizae is special the restriction not.Preferably, take the Radix Bupleuri of 100 parts by weight as the basis, herbal-composition can comprise the Rhizoma Coptidis of 10-30 parts by weight and the Radix Glycyrrhizae of 10-30 parts by weight.
The medical herbs of composition herbal-composition of the present invention according to common understanding, is divided into identical kind by those skilled in the art, can comprise any medical herbs that promotes the gastrointestinal motility effect that has.
Radix Bupleuri, Rhizoma Coptidis and Radix Glycyrrhizae may be contained in the compositions solvent extractable matter as medical herbs separately, or the medical herbs itself of pulverizing or dry herbal powder form.Therefore, the not special restriction of type or method.The solvent extractable matter of medical herbs can pass through water, organic solvent or its combination and extract they and respectively preparation or together preparation, and organic solvent can be C
1-C
4Alcohols, acetone, chloroform, dichloromethane, ether, ethyl acetate, hexane or its combination, but be not limited to this.C
1-C
4The example of alcohols can be methanol, ethanol, propanol and butanols, most preferred ethanol.
The solvent extractable matter of Radix Bupleuri, Rhizoma Coptidis and Radix Glycyrrhizae can be prepared by arbitrary extracting method known in the art, at 10 ° of C to 80 ° of C, carried out 10 to 80 hours under the preferred room temperature (about 25 ° of C), preferred 2 to 3 days, extracting method for example has hot water extraction, merceration extraction, returned cold to extract or supersound process, and preferred merceration extracts 1-5 time.The solvent extractable matter that filtration under diminished pressure obtains at 20 to 100 ° of C, under the preferred room temperature (about 25 ° of C), utilizes Rotary Evaporators concentrating under reduced pressure filtrate, thereby obtains final extract.
Herbal-composition of the present invention comprises two or more the combination that is selected from Radix Bupleuri, Rhizoma Coptidis and the Radix Glycyrrhizae, for prevention, improvement or treatment gastrointestinal motility obstacle disease, particularly effective to prevention, improvement or the treatment functional dyspepsia relevant with the gastrointestinal transmission with gastric emptying speed.Following examples have proved such effect.
In detail, in order to weigh it to the depression effect of the gastric emptying speed that postpones, give 24 hours Oral Administration in Rats of fasting herbal-composition of the present invention once, oral semisolid test meal then, thus the weight of measuring stomach is calculated gastric emptying speed (GER).Compare with non-processed group (matched group), the result shows the significant depression effect of gastric emptying speed that postpones, finds that this effect is similar to the mosapride processed group as positive control.
Compare as main component with the extract of single administration Radix Bupleuri, Rhizoma Coptidis and Radix Glycyrrhizae, use the herbal-composition that comprises two or more combination and show the significantly excellent depression effect of the gastric emptying speed of delay, each composition is wherein used identical dosage.The result shows that being combined in prevention and the treatment gastrointestinal motility obstacle disease of they shows cooperative effect.
Check herbal-composition of the present invention for the curative effect of the anorexia that stress cause and delay gastric emptying speed with rat model, check this herbal-composition to the curative effect of drug induced gastrointestinal transmission inhibition with the rat model that atropine and dopamine are processed.The result shows, herbal-composition of the present invention shows the curative effect that transmission significantly improves to gastrointestinal.
In addition, herbal-composition of the present invention comprises the medical herbs of the quilt approval safety of for a long time tradition use, does not therefore almost have the worry of adverse side effect and toxicity, and this just can be for the purpose life-time service compositions of preventing or treating gastrointestinal disease.
Therefore, the pharmaceutical composition of one aspect of the present invention can comprise pharmaceutically acceptable carrier or additive.
This pharmaceutical composition can by conventional route (as oral, rectum, intravenous injection, intramuscular, subcutaneous, by in utero, the cerebral dura mater injection or inject by tricorn (intracerebroventricular)) be applied to mammal, comprise rat, mice, domestic animal and people.So pharmaceutical composition can be made typical medicaments preparation known in the art.Pharmaceutical composition can be made oral formulations, injectable formulation, suppository, percutaneous preparation and through nasal preparation, but is not limited to this.Can make any preparation, preferred liquid, suspension, powder, granule, tablet, capsule, pill, emulsion, syrup, aerosol or oral formulations, for example extract.
After being mixed with such preparation, can add each preparation required pharmaceutically acceptable carrier or additive.After being mixed with oral formulations, can select in diluent, lubricating oil, binding agent, disintegrating agent, sweeting agent, stabilizing agent and the antiseptic one or more as carrier, can select in flavour enhancer, vitamin and the antioxidant one or more as additive.
Carrier and additive can be any pharmaceutically acceptable examples.Specifically, the example of preferred diluent can comprise: lactose, glucose, sucrose, corn starch, Oleum Glycines, microcrystalline Cellulose, sorbitol, xylitol and mannitol, the example of preferred lubricant can comprise: magnesium stearate and Talcum, the example of preferred binder can comprise: polyvinylpyrrolidone or hydroxypropyl cellulose.In addition, the example of preferred disintegrating agent can comprise: carboxymethylcellulose calcium, carboxymethylstach sodium, polyacrylic acid potassium or crospovidone, the example of preferred sweeting agent can comprise: white sugar, fructose, sorbitol or aspartame, the example of preferred stabilizing agent can comprise: sodium carboxymethyl cellulose, beta-schardinger dextrin-, hundred Apis cerana Fabriciuss and xanthan gum (Xhantan gum), the example of preferred antiseptic can comprise: methyl parahydroxybenzoate, propyl p-hydroxybenzoate and potassium sorbate.
Except these compositions, also can comprise be used to the additives known of improving taste, for example: natural flavouring, such as Fructus Pruni salicinae, Fructus Citri Limoniae, Fructus Ananadis comosi or medicinal herbs taste, natural fruit juice, natural dye, such as CHLOROPHYLLINE or flavonoid, sweetener component is such as fructose, Mel, sugar alcohol or sugar or acidulant such as citric acid or sodium citrate.
The example that is used for the preparation of parenteral dispenser comprises: aseptic aqueous solution, anhydrous solvent, suspension, emulsion, lyophilized preparation and suppository.In order to prepare anhydrous solvent and suspension, can use propylene glycol, Polyethylene Glycol, vegetable oil such as olive oil or injectable esters such as ethyl oleate.As suppository base, can use the glyceride of a witepsol(saturated fat acid blend), Polyethylene Glycol, Tween61, cocoa butter, lauric acid oil or glycerin gelatine.
Can change the proportion of composing pharmaceutical compositions of herbal ingredients in the scope of keeping treatment or prevention gastrointestinal motility obstacle disease effect, according to the present invention, compositions can comprise the herbal ingredients of 0.01-80 % by weight, preferred 1-50 % by weight.
In order to obtain to treat or prevent the effect of gastrointestinal motility obstacle disease, can be once a day or repeatedly use the active component of compositions, take the dry powder of solvent extractable matter as the basis, every daily dose is 0.01-10g/kg/ days, preferred 1-5g/kg/ days, the other drug that can take in according to patient's age, sex, body weight, diet, secretion rate or patient suitably determined.Therefore, the preparation of pharmaceutical composition should be considered the scope of effective dose, if necessary, also can and use the compositions personnel or specific dosage regimen is adjusted in professional judgement that the supervision compositions is used personnel according to individual demand, perhaps can use for several times at the predetermined time interval preparation medicament of each dosage unit.
The present invention's healthy functions food compositions on the other hand can comprise acceptable carrier or additive on the sitology.
Term used herein " healthy functions food " refers to a kind of healthy functions food, it contains the composition of listing in according in the composition tabulation of 2008-72 number approval of Korea S drug and food management board (KFDA), and has determined their functional and safety in healthy functions food amendment in 2008.
Healthy functions food compositions of the present invention can be formulated as typical healthy functions food article known in the art.Healthy functions food can be prepared as following form: powder, granule, tablet, pill, capsule, suspension, emulsion, syrup, injection (infusion), liquid, extract, chewing gum, tea, fruit jelly or beverage.Acceptable carrier or additive can be any carrier known in the art or additive on the sitology.
The healthy functions food compositions can comprise herbal ingredients, and based on the gross weight of food, herbal ingredients accounts for 0.01 to 15 % by weight of the present composition, preferred 0.2 to 10 % by weight, and based on the beverage of 100ml, herbal ingredients accounts for 0.1 to 30g, and preferred 0.2 to 5g.
Except above-mentioned herbal ingredients, this beverage also can comprise other components, and described other components can be various flavoring agents or the natural carbohydrates that uses in the conventional beverage.The example of above-mentioned natural carbohydrate is conventional sugar, and such as monosaccharide (such as glucose or fructose etc.), disaccharide (such as maltose, sucrose etc.) and polysaccharide (such as glucosan, cyclodextrin etc.), and sugar alcohol are such as xylitol, sorbitol and erythritol.Also can add other flavoring agents, natural flavouring (such as thaumatin (taumatin), Stevia rebaudiana (Bertoni) Hemsl extract etc.) and synthetic flavoring agent (such as glucide, aspartame etc.).Preferably, based on the beverage of 100ml, described natural carbohydrate content is approximately 1 to arrive 20g, preferred 5 to 12g.
The active component that pharmaceutical composition of the present invention and healthy functions food compositions comprise, namely, Radix Bupleuri, Rhizoma Coptidis and/or Radix Glycyrrhizae can show the gastrointestinal motility obstacle disease in the scope of prevention, improvement or therapeutic effect, simultaneously or with predetermined time intervening sequences use.When planning when predetermined time, the combination of Radix Bupleuri, Rhizoma Coptidis and/or Radix Glycyrrhizae was used at the interval, each active component prepares respectively.During two or more combination, their homogeneous mixture can be mixed with single dosage form in using simultaneously Radix Bupleuri, Rhizoma Coptidis and Radix Glycyrrhizae, perhaps they can prepare respectively, then each preparation are given simultaneously.
The invention mode
Below with reference to following examples the present invention is described in more detail.Only in order to illustrate, but the present invention is not limited to these embodiment to these embodiment.
Comparative example 1-3: the single extract of preparation Radix Bupleuri, Rhizoma Coptidis and Radix Glycyrrhizae
Dry Radix Bupleuri, Rhizoma Coptidis and Radix Glycyrrhizae are purchased from the oriental medicinal drug businessman, and water washes to remove impurity, and dry medical herbs is for the preparation of extract.Pulverize Radix Bupleuri, Rhizoma Coptidis and Radix Glycyrrhizae with grinder, every 200g adds the ethanol water of 400ml80%.Carry out merceration technique twice under the room temperature, amount to three days, thereby obtain each liquid extract.Filter each liquid extract, with Rotary Evaporators concentrating under reduced pressure under 50 ° of C, solvent is removed fully, and is dry in vacuum drying oven, thereby obtains dry ethanol extraction.Obtain the 31g Radix Bupleuri extract (comparative example 1) of powder type, 36g Rhizoma Coptidis extract (comparative example 2), and 48g Radix Glycyrrhizae extract (comparative example 3).
Embodiment 1-3: 2 kinds of combined extracts of preparation Radix Bupleuri, Rhizoma Coptidis and Radix Glycyrrhizae
Dry Radix Bupleuri, Rhizoma Coptidis and Radix Glycyrrhizae are available from the oriental medicinal drug businessman, and water washes to remove impurity, and dry medical herbs is for the preparation of extract.Pulverize Radix Bupleuri, Rhizoma Coptidis and Radix Glycyrrhizae with grinder, 780g Radix Bupleuri and 180g Rhizoma Coptidis (embodiment 1), 780g Radix Bupleuri and 180g Radix Glycyrrhizae (embodiment 2), and the Rhizoma Coptidis of each 500g and Radix Glycyrrhizae (embodiment 3) add in the extractor respectively.The ethanol water that adds 2L 80% in each combination, with method identical among the comparative example 1-3 extract, filter, concentrated and dry, thereby obtain the ethanol extraction of drying.Obtained 165g Radix Bupleuri-Rhizoma Coptidis extract (embodiment 1), 192g Radix Bupleuri-Radix Glycyrrhizae extract (embodiment 2) and 210g Rhizoma Coptidis-Radix Glycyrrhizae extract (embodiment 3).
Embodiment 4: the complex extraction thing of preparation Radix Bupleuri, Rhizoma Coptidis and Radix Glycyrrhizae extract
Dry Radix Bupleuri, Rhizoma Coptidis and Radix Glycyrrhizae are available from the oriental medicinal drug businessman, and water washes to remove impurity, and dry medical herbs is for the preparation of extract.
Pulverize Radix Bupleuri, Rhizoma Coptidis and Radix Glycyrrhizae with grinder, 6.5kg Radix Bupleuri, 1.5kg Rhizoma Coptidis and 1.5kg Radix Glycyrrhizae add in the extractor.The ethanol water that adds 20L 80%, with method identical among the embodiment 1-3 extract, filter, concentrated and dry, thereby obtain the ethanol extraction of drying.Radix Bupleuri-Rhizoma Coptidis of acquisition 1.6kg-Radix Glycyrrhizae extract.
EXPERIMENTAL EXAMPLE 1: the check herbal-composition is to postponing the depression effect of gastric emptying
In order to measure above-mentioned herbal-composition to postponing the depression effect of gastric emptying, use rat model to carry out following experiment.
At first, with 2 kinds of combinations of each Radix Bupleuri, Rhizoma Coptidis and Radix Glycyrrhizae extract and the embodiment 1-3 of comparative example 1-3, the complex extraction thing of the Radix Bupleuri of embodiment 4, Rhizoma Coptidis and Radix Glycyrrhizae is as experimental group, and mutually relatively they to the effect of gastric emptying speed.The water treatment group is organized in contrast, and the mosapride processed group is as positive control.
The male Sprague-Dawley rat in 7 ages in week is available from Jung-Ang Animal Lab. company limited.After week adaptation, use the healthy rat of body weight 270-280g.With the herbal-composition (20,60,200mg/kg) of preparation and as the 10mg/kg mosapride of positive control by oral administration to 24 hours rat of fasting once, and do not allow in 3 hours to drink water.After 60 minutes, use the by force semisolid test meal of Orally administered 2mL (at the 30g food of the methylcellulose of 90mL 0.5% preparation) of disposable probe.After 30 minutes of the semisolid test meal of feeding, use CO
2Then anesthetized animal carries out laparotomy ventrotomy, the excision stomach.Clamp cardiac end and the pylorus end of stomach, weigh.After weighing, along opening stomach than the deep camber place, go out gastric content with distilled water, then the empty stomach of drying is weighed.
The experiment triplicate, analysis result utilizes the measurement weight of semi-solid test meal residual in following mathematical expression 1 stomach function regulating to calculate average gastric emptying speed (GER).The result is as shown in table 1 below.
[mathematical expression 1]
Gastric emptying (%)=[1-(after the drug treating in the stomach in some stomach of the weight of residual semi-solid test meal/0th weight of residual semi-solid test meal)] x 100
[table 1]
Laboratory animal: SD rat, approach: Orally administered
* make comparisons with matched group and assess p-value (p＜0.05, Student's t-test)
As shown in table 1, to compare with using Radix Bupleuri, Rhizoma Coptidis and Radix Glycyrrhizae extract separately, two or more the combination of using in Radix Bupleuri, Rhizoma Coptidis and the Radix Glycyrrhizae of embodiment 1-3 is revealed significantly higher inhibition to postponing the gastric emptying speedometer.In addition, with use Radix Bupleuri, Rhizoma Coptidis and Radix Glycyrrhizae separately extract and two or more the combination of using them compare, Radix Bupleuri, Rhizoma Coptidis and the Radix Glycyrrhizae complex extraction thing of using embodiment 4 show significantly higher inhibition.
Therefore, the result shows, compares with single administration, and the complex extraction thing of two or more shows cooperative effect in Radix Bupleuri of the present invention, Rhizoma Coptidis and the Radix Glycyrrhizae in prevention or the treatment gastrointestinal motility obstacle disease relevant with functional dyspepsia.In addition, can find out, the medical herbs complex of embodiment 4 reveals significant depression effect to postponing the gastric emptying speedometer, with similar as the mosapride for the treatment of functional dyspepsia at present.
EXPERIMENTAL EXAMPLE 2: herbal-composition is to retraining the effect of the apositia that stress cause
Based on the result of EXPERIMENTAL EXAMPLE 1, use rat model to carry out following experiment, with the herbal-composition of measuring preparation among the embodiment 4 effect to the gastrointestinal transmission.
7 the week age male Sprague-Dawley rat available from Jung-Ang Animal Lab. company limited.After week adaptation, use body weight to be used for experiment at the healthy rat of 270-280g.Be the beneficial effect of assessing anorexia, rat fasting 20 hours, and do not allow in 3 hours to drink water, then in limiter, limited 6 hours, bringing out stress.Then, carry out once Orally administeredly with the contrast mosapride of the herbal-composition of 3,10 and 30mg/kg of embodiment 4 preparation and 3mg/kg, then in limiter, limited again 60 minutes.Normal rat carries out Orally administered with carrier, not inducing stress.After the drug treating, with the food of weighing the in advance rat of feeding, the timing of feedstuff feeding time is 30min.The result is as shown in table 2 below.The methylated cellulose aqueous solution of use 0.5% is as carrier.
[table 2]
Laboratory animal: SD rat (N=8), approach: Orally administered
* make comparisons with normal group and assess p-value (p＜0.05, Student's t-test)
As a result, all not observing the apositia that stress cause in all groups that the herbal-composition of embodiment 4 is processed and mosapride processed group improves significantly.But in the processed group with the 30mg/kg herbal-composition, observe the apositia that stress cause 22.6% improvement is arranged, show better than the result of positive control mosapride.
EXPERIMENTAL EXAMPLE 3: herbal-composition is to retraining the effect of the delayed gastric emptying that stress cause
For the herbal-composition of the measuring embodiment 4 preparation effect to the gastrointestinal transmission, carry out following experiment with rat model.
7 the week age male Sprague-Dawley rat available from Jung-Ang Animal Lab. company limited.After week adaptation, use body weight to be used for experiment at the healthy rat of 270-280g.Be assessment to the impact of gastric emptying speed, rat fasting 24 hours can not be drunk water in 3 hours before the drug treating, then used 1,3,10,30 and the medical herbs complex extraction thing of embodiment 4 preparations of 100mg/kg and the positive control itopride of 30mg/kg.After the drug treating 60 minutes, allow the food of the 1.5g that rats eating weighs in advance, amount to 10 minutes, measure the food consumption situation.Then rat is limited in limiter 90 minutes stress to induce.Induce stress rat CO
2Gas kills, the excision stomach.Remove gastric content, thereby dry stomach calculates gastric emptying speed.The result is as shown in table 3 below.
[table 3]
Laboratory animal: SD rat (N=8), approach: Orally administered
* make comparisons with normal group and assess p-value (p＜0.05, Student's t-test)
# and stress-induced group are made comparisons and are assessed p-value (p＜0.05, Student's t-test)
As a result, compare (π＜0.05) with the stress-induced group, in the herbal-composition processed group of 3mg/kg embodiment 4, the delayed gastric emptying of observing the constraint stress-induced is significantly improved.And the delayed gastric emptying that the herbal-composition of 100mg/kg shows stress-induced has higher depression effect.
EXPERIMENTAL EXAMPLE 4: the effect of the gastrointestinal transmission delay that herbal-composition is induced atropine
For the impact that the herbal-composition of measuring preparation among the embodiment 4 transmits gastrointestinal, use rat model to carry out following experiment.
The male Sprague-Dawley rat in 7 ages in week is available from Jung-Ang Animal Lab. company limited.After week adaptation, use body weight to be used for experiment at the healthy rat of 270-280g.Rat fasting 24 hours, and with the atropine intraperitoneal administration of 1.5mg/kg.Rat is oral respectively at once to give 10,30 and the herbal-composition of embodiment 4 preparation of 100mg/kg, and the itopride of 30mg/kg and the mosapride of 3mg/kg are as positive control.After one hour, the oral semi-solid test meal that contains the 0.05% phenol red thing that serves as a mark that gives every rat 2ml.After 30 minutes, rat is imposed euthanasia, the excision small intestinal.The distance that the total length of measurement small intestinal and label move along small intestinal from the pylorus part is calculated the gastrointestinal transmission.Experiment repeats twice, editor and analysis result.Take value of calculation as the basis, analyze the significance,statistical of gastrointestinal transmission speed between experimental group and the matched group with Student's t-test, therefore compared mutually the gastrointestinal transmission between normal group, positive controls and the experiment material processed group, the result is as shown in table 4 below.
[table 4]
* make comparisons with matched group and assess p-value (p＜0.05, Student's t-test)
# and normal group are made comparisons and are assessed p-value (p＜0.05, Student's t-test)
Compare with matched group, use 30 and the herbal-composition of 100mg/kg embodiment 4 significantly improved the gastrointestinal transmission delay that atropine is induced.On the contrary, positive controls, itopride (30mg/kg) and mosapride (3mg/kg) processed group do not demonstrate the obvious effect of improving the gastrointestinal transmission.
Delay gastrointestinal transmission due to these results suggest, the herbal-composition antagonism atropine blocking-up muscarinic receptor of embodiment 4 promotes gastrointestinal motility in the dose dependent mode, thereby can be developed into the therapeutic agent of functional dyspepsia (FD).
EXPERIMENTAL EXAMPLE 5: herbal-composition is to the effect of the gastrointestinal transmission delay of Induced by Dopamine
For the effect that the herbal-composition of measuring embodiment 4 preparations transmits gastrointestinal, use rat model to carry out following experiment.
The male Sprague-Dawley rat in 7 ages in week is available from Jung-Ang Animal Lab. company limited.After week adaptation, use body weight to be used for experiment at the healthy rat of 270-280g.Rat fasting 24 hours orally gives rat herbal-composition (10,30,100mg/kg) and as itopride (30mg/kg) and the mosapride (3mg/kg) of positive control.After 1 hour, intraperitoneal gives the dopamine of rat 1.5mg/kg.To every rat immediately the oral 2ml of giving contain the semi-solid test meal of the 0.05% phenol red thing that serves as a mark.After 30 minutes, rat is carried out euthanasia, the excision small intestinal.The distance that the total length of measurement small intestinal and label move along small intestinal from the pylorus part is calculated gastrointestinal transmission situation.Take value of calculation as the basis, analyze the significance,statistical of gastrointestinal transmission speed between experimental group and the matched group with Student'st-test, therefore compared mutually the gastrointestinal transmission between positive controls and the experiment material processed group, the result is as shown in table 5 below.
[table 5]
Laboratory animal: SD rat (N=8), approach: Orally administered
* make comparisons with matched group and assess p-value (p＜0.05, Student's t-test)
# and normal group are made comparisons and are assessed p-value (p＜0.001)
The gastrointestinal transmission result (%) that total length by measuring small intestinal and the displacement of mark are calculated shows, compare (only processing with dopamine) with matched group, normal group (not having dopamine) demonstrates higher gastrointestinal transmission, shows that the dopamine processing has significantly postponed the gastrointestinal transmission.
Use 30 and the herbal-composition of 100mg/kg embodiment 4 significantly improved gastrointestinal transmission (p＜0.05) in the dose dependent mode.In control substance of plant drug, compare with matched group, dopamine-receptor antagonist, itopride (30mg/kg) has remarkable result (p=0.002) to improving the gastrointestinal transmission, but mosapride (3mg/kg) does not have.
Preparation Example 1: the preparation of tablet
According to following composition, by wet method and non-slurry pelletizing method, the herbal-composition for preparing with embodiment 4 prepares granule, and then tabletting is to make the tablet for oral administration.
Herbal-composition ... ... ... ... ... 200mg
Light anhydrous silicic acid ... ... ... ... 10mg
Magnesium stearate ... ... ... ... ... ..2mg
Microcrystalline Cellulose ... ... ... ... ..50mg
Sodium Carboxymethyl Starch ... ... ... ... ..25mg
Corn starch ... ... ... ... ... ... .113mg
Dehydrated alcohol (Ethanol absolute) and pure water ... .. is an amount of
Preparation Example 2: the preparation of capsule
According to following composition, pack the herbal-composition of embodiment 4 preparations into gelatine capsule with the preparation capsule.
Herbal-composition ... ... ... ... ... ..300mg
Lactose ... ... ... ... ... ... ..50mg
Starch ... ... ... ... ... ... ... 50mg
Talcum ... ... ... ... ... ... ... ..2mg
Magnesium stearate ... ... ... ... .. is an amount of
Preparation Example 3: the preparation of ointment
According to following composition, use the herbal-composition of embodiment 4 preparations to prepare ointment.
Herbal-composition ... ... ... ... ... 5g
Cetin ... ... ... ... ... ..20g
Spermol ... ... ... ... ... ... .40g
Stearyl alcohol ... ... ... ... ... ..40g
Isopropyl myristate ... ... ... ... ... .80g
The anhydrosorbitol monostearate ... ... ... ... ..20g
Polysorbate ... ... ... ... ... ... 60g
Propyl p-hydroxybenzoate ... ... ... ... ..1g
Methyl parahydroxybenzoate ... ... ... ... ..1g
Phosphoric acid and pure water ... .... an amount of
Preparation Example 4: the preparation of injection
According to following composition, use the herbal-composition of embodiment 4 preparations to prepare injection.
Herbal-composition ... ... ... ... ... 100mg
Mannitol ... ... ... ... ... ... ... .180mg
Sodium hydrogen phosphate ... ... ... ... .25mg
Methyl parahydroxybenzoate ... ... ... ... ... ... ..0.8mg
Propyl p-hydroxybenzoate ... ... ... ... ... ... ..0.1mg
Injectable sterile water ... ... .... an amount of
Preparation Example 5: the preparation of liquid preparation
According to following composition, use the herbal-composition of embodiment 4 preparations to prepare liquid preparation.
Herbal-composition ... ... ... ... ... 300mg
Sugar ... ... ... ... ... ... ... .20g
The corn syrup of high fructose ... ... ... ... .20g
The Fructus Citri Limoniae flavoring agent ... ... ... ... ... .. is an amount of
Pure water ... ... ... ... ... .. adds to 100mL
Preparation Example 6: the preparation of powder medicine
According to following composition, the herbal-composition mixing with all compositions and embodiment 4 preparations is filled in sealed bladder, thus the preparation powder medicine.
Herbal-composition ... ... ... ... ... 0.2g
Lactose ... ... ... ... ... ... ... ..1.5g
Talcum ... ... ... ... ... ... ... .0.5g
Preparation Example 7: the preparation of pill
The Mel of heating and filtration 100mL, this step repeats three or four times, until become glutinous, forms yellow line, but tack-free finger after cooling off.Water, Semen Castaneae oil and vinegar can be used for replacing Mel.The 5g herbal-composition of embodiment 4 preparations is added in the Mel of heating, carry out kneading.With the pill forming machine mixture is made uniform ball, thereby be prepared into pill.The pill of preparation is dry in nice and cool and dry place, then seals and stores in the place of nice and cool and lucifuge.
Preparation Example 8: the preparation of suspension
The herbal-composition of 0.1g embodiment 4 preparation is added to 100mL contains in Polyethylene Glycol, polyvinylpyrrolidone, carboxymethyl cellulose, bentonite or the Tween 80 water as suspending agent, and mix.According to typical preparation method, mix saccharin sodium, syrup, white sugar, Mel or D-Maltose alcohol as sweeting agent, thus supending.
Preparation Example 9: the preparation of preparation capable of permeating skin
According to following composition, use the herbal-composition of embodiment 4 preparations, prepare preparation capable of permeating skin by typical method.
Herbal-composition ... ... ... ... ... 0.4mg
Sodium polyacrylate ... ... ... ... ... 1.3g
Glycerol ... ... ... ... ... ... ..3.6g
Aluminium hydroxide ... ... ... ... ... 0.04g
Methyl parahydroxybenzoate ... ... ... ... ... ... 0.2g
Pure water is an amount of
Preparation Example 10: the preparation of Chewing gum
According to following composition and content, use the herbal-composition of embodiment 4 preparations to prepare Chewing gum by typical method.
Herbal-composition ... ... ... ... .0.24 ~ 0.61%
Gum base ... ... ... ... ... ... ..20%
Sugar ... ... ... ... ... ... 76.36 ~ 76.76%
Flavoring agent of fruit ... ... ... ... ... ... 1%
Pure water ... ... ... ... ... .2%
Preparation Example 11: the preparation of beverage
According to following composition and content, use the herbal-composition of embodiment 4 preparations to prepare beverage by typical method.
Herbal-composition ... ... ... ... .0.5g ~ 1.3g
Mel ... ... ... ... ... ... ... 522mg
Thioctamide ... ... ... ... ... .5mg
Nicotiamide ... ... ... ... ..10mg
Riboflavin sodium salt hydrochlorate ... ... ... .3mg
Pyridoxine hydrochloride ... ... ... ... ..2mg
Inositol ... ... ... ... ... ... ..30mg
Orotic acid ... ... ... ... ... ... .50mg
Pure water ... ... ... ... ... 300mL
Preparation Example 12: the preparation of confection
According to following composition and content, by typical method, use the herbal-composition of embodiment 4 preparations to prepare confection.
Herbal-composition ... ... ... ... ... 20%
The crystallization lactose ... ... ... ... ..80%
Pure water ... ... ... ... .. is an amount of
Acesulfame potassium ... ... ... ... .... an amount of
The blue berry flavoring agent ... ... ... .... an amount of
Citric acid ... ... ... ... ... an amount of
The mixture of the herbal-composition with 20% and 80% crystallization lactose dilutes with pure water, places steamer.At first prepare burden until all substances become solvable in high temperature plate (high-temperature plate) heating.Then be transferred in the vacuum cooking stove, continue heating.The admixture that obtains forms the viscosity agglomerate in lower temperature.Syrup is transferred to back shroud (rear plate) from cooking stove, processes (drop rolling) thereby its hardening is fit to drip roller.Make lump pass through to drip roller.The moulding one-tenth of confection had acceptable quality.
Preparation Example 13: the preparation of wine
Clean 650g Radix Bupleuri, 150g Rhizoma Coptidis and 150g Radix Glycyrrhizae, and place extractor.Add 10,000mL water, concentrate approximately 3 hours at 100 ° of C, thereby obtain liquid extract.The tradition bent (nuruk) of the rice of respectively the 4kg rice being made, 1kg, and the mother solution of 5kg carries out intimate mixing, adds liquid extract, then 10-25 ° of C fermented approximately 3 days.Thereby filtering fermentating liquid separates liquid with solid, and heats under 55-60 ° of C.In filtrate, add pure water to 10,000mL, thus be prepared into wine (liquor).
Claims (7)
1. pharmaceutical composition that is used for prevention or treatment gastrointestinal motility obstacle disease, described pharmaceutical composition comprise and are selected from lower group two or more combination: Radix Bupleuri, Rhizoma Coptidis and Radix Glycyrrhizae.
2. healthy functions food compositions that is used for prevention or improves the gastrointestinal motility obstacle disease, described compositions comprise and are selected from lower group two or more combination: Radix Bupleuri, Rhizoma Coptidis and Radix Glycyrrhizae.
3. compositions as claimed in claim 1 or 2 is characterized in that, take the Radix Bupleuri of 100 weight portions as the basis, described compositions comprises the Rhizoma Coptidis of 10-30 parts by weight and the Radix Glycyrrhizae of 10-30 parts by weight.
4. compositions as claimed in claim 1 or 2 is characterized in that, Radix Bupleuri, Rhizoma Coptidis and Radix Glycyrrhizae respectively do for oneself: the medical herbs of itself pulverizing, the herbal powder of drying or the crude extract of solvent, described solvent is selected from lower group: water, C
1-C
4Alcohols and their combination.
5. compositions as claimed in claim 1 or 2 is characterized in that, described gastrointestinal motility obstacle disease is the functional dyspepsia relevant with the gastric emptying speed that postpones or gastrointestinal transmission.
6. compositions as claimed in claim 1 is characterized in that, the form of described compositions is: powder, granule, tablet, capsule, suspension, emulsion, syrup, liquid, aerosol, extract, injectable formulation, percutaneous preparation or suppository.
7. compositions as claimed in claim 2 is characterized in that, the form of described compositions is: liquid, suspension, powder, granule, tablet, capsule, pill, extract, tea, fruit jelly or beverage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510131304.6A CN104800309A (en) | 2010-05-06 | 2011-05-06 | A pharmaceutical composition and a health functional food composition for preventing, treating or improving a gastrointestinal dyskinetic disease |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2010-0042585 | 2010-05-06 | ||
| KR1020100042585A KR101263191B1 (en) | 2010-05-06 | 2010-05-06 | A pharmaceutical composition and a health functional food composition for preventing, treating or improving a gastrointestinal dyskinetic disease |
| PCT/KR2011/003397 WO2011139118A2 (en) | 2010-05-06 | 2011-05-06 | A pharmaceutical composition and a health functional food composition for preventing, treating or improving a gastrointestinal dyskinetic disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510131304.6A Division CN104800309A (en) | 2010-05-06 | 2011-05-06 | A pharmaceutical composition and a health functional food composition for preventing, treating or improving a gastrointestinal dyskinetic disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102858357A true CN102858357A (en) | 2013-01-02 |
Family
ID=44904245
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510131304.6A Pending CN104800309A (en) | 2010-05-06 | 2011-05-06 | A pharmaceutical composition and a health functional food composition for preventing, treating or improving a gastrointestinal dyskinetic disease |
| CN2011800084088A Pending CN102858357A (en) | 2010-05-06 | 2011-05-06 | A pharmaceutical composition and a health functional food composition for preventing, treating or improving a gastrointestinal dyskinetic disease |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510131304.6A Pending CN104800309A (en) | 2010-05-06 | 2011-05-06 | A pharmaceutical composition and a health functional food composition for preventing, treating or improving a gastrointestinal dyskinetic disease |
Country Status (7)
| Country | Link |
|---|---|
| KR (1) | KR101263191B1 (en) |
| CN (2) | CN104800309A (en) |
| BR (1) | BR112012020342A2 (en) |
| MY (1) | MY162542A (en) |
| RU (1) | RU2540511C2 (en) |
| UA (1) | UA105685C2 (en) |
| WO (1) | WO2011139118A2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104622989A (en) * | 2015-01-15 | 2015-05-20 | 西安医学院 | Traditional Chinese medicine compound sterilizing agent and preparation method thereof |
| CN105169204A (en) * | 2015-09-29 | 2015-12-23 | 济南邦文医药科技有限公司 | Traditional Chinese medicine composition for treating gastrointestinal motility dysfunction after ventriculo-peritoneal shunt operation |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102014922B1 (en) * | 2014-08-13 | 2019-08-27 | (주)뉴트리 | Composition for improving digestive functions comprising glabridin from Liquorice |
| CN111214578A (en) * | 2020-03-17 | 2020-06-02 | 苏州梅氏健康产业管理有限公司 | Traditional Chinese medicine bathing liquid acting on digestive system and preparation method thereof |
| KR102407619B1 (en) | 2020-03-24 | 2022-06-13 | (주)에이앤바이오 | Composition for improving cat hairball discharge |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1768816A (en) * | 2004-05-29 | 2006-05-10 | 熊烈 | Gastric motility medicine |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7198804B2 (en) * | 2002-04-12 | 2007-04-03 | Helixir Co., Ltd. | Crude drug composition for preventing and treating gastrointestinal dyskinetic diseases |
| KR100543354B1 (en) * | 2005-05-17 | 2006-01-20 | 김성호 | Herb extract having anti-Hepatitis activity |
| CN100544764C (en) * | 2006-08-09 | 2009-09-30 | 厦门臻琪投资管理有限公司 | Neurasthenic Chinese medicine composition of a kind of treatment and preparation method thereof |
| KR101099004B1 (en) * | 2009-03-13 | 2011-12-28 | 주식회사 사이그린 | A composition for preventing or treating a gastrointestinal disease |
-
2010
- 2010-05-06 KR KR1020100042585A patent/KR101263191B1/en active IP Right Grant
-
2011
- 2011-05-06 CN CN201510131304.6A patent/CN104800309A/en active Pending
- 2011-05-06 UA UAA201209654A patent/UA105685C2/en unknown
- 2011-05-06 WO PCT/KR2011/003397 patent/WO2011139118A2/en active Application Filing
- 2011-05-06 MY MYPI2012003532A patent/MY162542A/en unknown
- 2011-05-06 BR BR112012020342A patent/BR112012020342A2/en not_active Application Discontinuation
- 2011-05-06 RU RU2012134195/15A patent/RU2540511C2/en active
- 2011-05-06 CN CN2011800084088A patent/CN102858357A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1768816A (en) * | 2004-05-29 | 2006-05-10 | 熊烈 | Gastric motility medicine |
Non-Patent Citations (2)
| Title |
|---|
| GANG CHEN 等: "《Isoliquiritigenin, a Flavonoid from Licorice,plays a Dual Role in regulating Gastrointestinal Motility in vitro and in vivo》", 《PHYTOTHERAPY RESEARCH》 * |
| 赵海顺: "调胃消胀汤治疗功能性消化不良69例", 《陕西中医》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104622989A (en) * | 2015-01-15 | 2015-05-20 | 西安医学院 | Traditional Chinese medicine compound sterilizing agent and preparation method thereof |
| CN105169204A (en) * | 2015-09-29 | 2015-12-23 | 济南邦文医药科技有限公司 | Traditional Chinese medicine composition for treating gastrointestinal motility dysfunction after ventriculo-peritoneal shunt operation |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2012134195A (en) | 2014-06-20 |
| RU2540511C2 (en) | 2015-02-10 |
| MY162542A (en) | 2017-06-15 |
| WO2011139118A3 (en) | 2012-04-19 |
| CN104800309A (en) | 2015-07-29 |
| UA105685C2 (en) | 2014-06-10 |
| WO2011139118A2 (en) | 2011-11-10 |
| KR20110123114A (en) | 2011-11-14 |
| BR112012020342A2 (en) | 2016-05-03 |
| KR101263191B1 (en) | 2013-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100980819B1 (en) | The composition comprising complex herbal extract as an active ingredient and the preparation method thereof | |
| CN102365091A (en) | Compositions for preventing or improving gastrointestinal diseases | |
| KR101793531B1 (en) | A composition and functional food comprising an combination extract of Atractylodes macrocephala KOIDZ, Morus alba L., Lycium chinensis, Euphoria lingan STEUD, Achyranthus japonica NAKAI, Eucommia ulmoides OLIV and Asparagus cochinchinensis MERR for preventing or treating postmenopause syndrome | |
| CN102858357A (en) | A pharmaceutical composition and a health functional food composition for preventing, treating or improving a gastrointestinal dyskinetic disease | |
| KR102192573B1 (en) | Composition for preventing and improving menstrual pain and skin troubles | |
| KR100585562B1 (en) | Crude drug composition for treating or alleviating inflammatory disease | |
| KR102014922B1 (en) | Composition for improving digestive functions comprising glabridin from Liquorice | |
| KR102216219B1 (en) | Pharmaceutical composition comprising the extract of rodgersia podophylla as an effective component for prevention or treatment of diabetes and health functional food comprising the same | |
| KR100522176B1 (en) | Composition for improving male sexual function | |
| KR20120109785A (en) | Composition for treatment of lung cancer and functional food comprising extract of inulae flos | |
| KR20120089045A (en) | A composition comprising powder of amphicarpaea bracteata subsp.edgeworthii(benth.) h.ohashi and the extract thereof for preventing and treating diabetes mellitus and diabetic complication | |
| KR20170055081A (en) | A composition for preventing or treating menopausal disorder comprising Tetragonia tetragonoides (Pall.) Kuntze extract | |
| KR100638344B1 (en) | Composition comprising the crude drug extract for improving eye symptoms of VDT syndrome | |
| KR20160059152A (en) | Anti-obesity composition comprising Cirsium japonicum leaf extract as effective component | |
| KR101618215B1 (en) | The pharmaceutical compositions for prevention or treatment of male infertility containing Rehmannia glutinosa Liboschitz var.purpurae Makino, Lycium chinense Miller, Aquillaria agallocha Roxburgh, Poria cocos Wolf, Panax ginseng C.A. Meyer and honey as a active ingredient | |
| KR20150031373A (en) | Phamaceutical and food composition for preventing or treating obesity comprising extract of leaf from Hoppophea rhamnoids as effective component | |
| KR20060030575A (en) | Pharmaceutical composition comprising the complex crude drug extract for preventing and treating hyperthyroidism | |
| KR102217732B1 (en) | Composition for preventing and improving the development of premature pseudo-breast | |
| CN111759901B (en) | Traditional Chinese medicine composition for treating functional abdominal pain of children and preparation method thereof | |
| CN102302617A (en) | Traditional Chinese medicinal preparation for invigorating stomach, relaxing bowel and reducing blood fat and preparation method thereof | |
| US20230405071A1 (en) | Compositions and methods useful for management of blood sugar | |
| WO2020091266A1 (en) | Composition comprising elderberry extract as effective component for preventing, treating, or alleviating male subfertility | |
| KR20230064049A (en) | Extract of herbal medicine mixture for prevention, improvement or treatment of polycystic ovarian syndrome | |
| CN104997937B (en) | A kind of blood sugar reducing food containing fructus lycii, health care product or pharmaceutical composition | |
| KR20230172271A (en) | Compositions for preventing or treating nonalcoholic steatohepatitis comprising extracts of Asiasarum sieboldi, Platycodon grandiflorum and Cinnamomum cassia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: CJ HEALTHCARE CO., LTD. Free format text: FORMER OWNER: CJ CORP. Effective date: 20150105 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20150105 Address after: Seoul, South Korea Applicant after: CJ CHEILJEDANG CORPORATION Applicant after: Scigreen Address before: Seoul, South Korea Applicant before: CJ Corp. Applicant before: Scigreen |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130102 |